Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (Nasdaq: SABS), or SAB BIO, generates frequent news as a clinical-stage biopharmaceutical company advancing fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders. Most recent headlines focus on SAB-142, the company’s multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for autoimmune type 1 diabetes (T1D) in new-onset, Stage 3 patients.
News updates commonly cover clinical milestones for SAB-142, including Phase 1 trial results and the launch and progress of the Phase 2b registrational SAFEGUARD study. Releases describe safety, pharmacodynamic, and immunogenicity findings, such as the absence of serum sickness and anti-drug antibodies in the Phase 1 trial, as well as the design and enrollment status of the SAFEGUARD trial at multiple centers around the world.
SABS news also highlights SAB BIO’s scientific presence at major medical meetings. The company regularly announces oral and poster presentations at conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management. These items detail new data on SAB-142’s mechanism of action, immunomodulatory effects without sustained lymphodepletion, and pharmacokinetic profiling.
Investors and observers will also find corporate and investor-relations updates, including participation in healthcare investor conferences and changes to the Board of Directors, as well as summaries of quarterly financial results and business highlights. For anyone tracking SABS, this news feed provides an ongoing view into SAB BIO’s clinical development progress, scientific communications, governance developments, and key events related to its lead program SAB-142 and its broader human IgG platform.
SAB BIO (Nasdaq: SABS) announced positive confirmatory Phase 1 results for SAB-142, an hATG candidate for stage 3 type 1 diabetes (T1D). In 68 treated participants (healthy volunteers and T1D patients), SAB-142 showed 0% serum sickness (0/68), 0% anti-drug antibody events (0/68), no drug-related serious adverse events, and transient lymphopenia that resolved to baseline within 1–3 days in 100% of subjects (68/68). Most adverse events were mild and infusion-related. A registrational Phase 2b SAFEGUARD trial is underway and recruiting globally, with the company on track to dose the first patient by year-end.
SAB BIO (Nasdaq: SABS) will present clinical data on SAB-142 at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia), December 9-11, 2025 in Singapore. Presentations on December 10, 2025 highlight Phase 1 results reporting a multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile without serum sickness or anti-drug antibodies at the target dose.
The company said it is currently in Phase 2b development for delaying progression of new-onset Stage 3 type 1 diabetes and expects to report additional Phase 1 data and dose the first Phase 2b SAFEGUARD patient later in 2025. Presentations will be posted on the company website.
SAB BIO (Nasdaq: SABS) initiated its registrational Phase 2b SAFEGUARD trial of lead candidate SAB-142 in new-onset Stage 3 T1D, activated multiple sites in the US, Australia and New Zealand, and is on-track to dose the first patient by year-end 2025. The company reported a strong cash position of $161.5 million at Sept 30, 2025 (vs. $20.8 million at Dec 31, 2024) and said its runway extends through 2028. Phase 1 data presented at EASD and ISPAD showed a favorable safety profile, no serum sickness or anti-drug antibodies at the target dose, and sustained immunomodulation. Financials: Q3 R&D $9.0M, other income $58.1M, and Q3 net income $45.4M. Company expects SAFEGUARD data in 2H 2027 and to present additional Phase 1 redosing data by year-end 2025.
SAb Biotherapeutics (Nasdaq: SABS) will present clinical and translational data for its lead program SAB-142 at the 51st ISPAD Annual Conference in Montréal, Nov 5–8, 2025.
Six presentations (four oral, two posters) describe Phase 1 results showing a multi-specific mechanism of action with sustained immunomodulation, a favorable safety profile at target dose without serum sickness or anti-drug antibodies, and a novel pharmacokinetic assay for measuring SAB-142.
The presentations cover specimen quality methods, binding specificity profiling, immunomodulation without sustained lymphodepletion, mechanism of action, PK assay details, and safety findings, led by SAB BIO scientific and clinical leaders.
SAb Biotherapeutics (Nasdaq: SABS) announced that members of management will participate in three investor conferences in November–December 2025: a UBS Global Healthcare Conference fireside chat on Nov 10, 2025 at 2:45 p.m. ET in West Palm Beach, a Guggenheim Healthcare Innovation Conference fireside chat on Nov 12, 2025 at 10:00 a.m. ET in Boston, and an Evercore Healthcare Conference fireside chat on Dec 2, 2025 at 3:50 p.m. ET in Coral Gables.
Live webcasts and archived recordings will be available on the company Investor Relations Events page at www.sab.bio.
SAB Biotherapeutics (NASDAQ: SABS) presented multiple studies at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), highlighting data for their novel SAB-142 treatment for type 1 diabetes (T1D).
The presentations featured results from their Phase 1 clinical study of SAB-142, a fully human anti-thymocyte immunoglobulin (ATG), which demonstrated sustained immunomodulation without causing prolonged lymphodepletion. The company also shared data about SAB-142's pharmacokinetic profile and discussed the INNODIA-sponsored MELD-ATG study, which validated the disease-modifying potential of ATG therapy in T1D patients.
SAB BIO is currently initiating its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, collaborating with INNODIA and leading European T1D centers.
SAB Biotherapeutics (Nasdaq: SABS) announced its participation at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, from September 15-19, 2025. The company will deliver five presentations focused on SAB-142, their novel immunotherapy treatment for type 1 diabetes.
The presentations include an INNODIA-hosted symposium and four oral presentations covering various aspects of SAB-142, including its immunomodulation properties, mechanism of action, pharmacokinetic assays, and specimen quality analysis for clinical trials. Key speakers include Dr. Alexandra Kropotova, EVP and Chief Medical Officer, Dr. Christoph Bausch, EVP and Chief Operating Officer, and Dr. Eric Sandhurst, Director of Program Management.
SAB BIO (Nasdaq: SABS) has announced significant developments in Q2 2025, highlighted by a $175 million oversubscribed private placement that included strategic investor Sanofi. The financing extends the company's operational runway until mid-2028 and will fully fund their pivotal Phase 2b SAFEGUARD study for SAB-142, their lead candidate for delaying type 1 diabetes progression.
The company achieved FDA alignment on the SAFEGUARD study design, scheduled to begin in Q3 2025. The private placement included issuing 1 million shares of Series B preferred stock at $1.75 per share conversion price, plus warrants for potential additional proceeds of $284 million.
Financial results showed cash position of $5.7 million as of June 30, 2025, with Q2 R&D expenses at $7.0 million and a net loss of $10.1 million.
SAB BIO (Nasdaq: SABS) has secured a significant $175 million private placement with participation from strategic investor Sanofi and several prominent institutional investors. The oversubscribed financing includes the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock at a conversion price of $1.75 per share.
The company will also issue warrants that could provide up to an additional $284 million in gross proceeds if exercised in full. The proceeds will fund the pivotal Phase 2b SAFEGUARD study of SAB-142 for delaying progression of autoimmune Type 1 Diabetes (T1D) in newly diagnosed patients, extending the company's cash runway into mid-2028.
SAB BIO (NASDAQ: SABS) has reported its Q1 2025 financial results and company updates. The clinical-stage biopharmaceutical company completed patient dosing in the last cohort of the Phase 1 clinical study of SAB-142, their novel immunotherapy for delaying type 1 diabetes progression. The company reported cash and equivalents of $12.9 million, down from $20.8 million in December 2024.
Financial highlights include R&D expenses of $7.7 million (down from $8.1 million YoY), reduced G&A expenses of $3.1 million (down from $4.2 million YoY), and other income of $5.6 million. The company reported a net loss of $5.2 million. SAB BIO also achieved a significant milestone by obtaining a Qualified Person declaration for their in-house CMC manufacturing process, enabling them to meet European manufacturing standards for upcoming EU clinical trials.